

- **Name:** Joon Oh Park, MD, PhD
 - **Current Position & Affiliation:** Professor
Samsung Medical Center, Sungkyunkwan University
School of Medicine, Seoul, Korea
 - **Country:** Republic of Korea
-

- **Educational Background:**

- MD (1991): Yonsei University College of Medicine, Seoul, Korea
- Master (1995): Yonsei University Graduate School of Medical Science, Seoul, Korea
- PhD (2001): Yonsei University Graduate School of Medical Science, Seoul, Korea

- **Professional Experience:**

- Clinical fellow (1999-2001): Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea
- Clinical fellow (2001-2002): Division of Hematology-Oncology Samsung Medical Center
- Assistant Professor (2002-2007): Samsung Medical Center, Sungkyunkwan Univ. School of Medicine
- Postdoc. Fellow (2006-2008): Dana-Farber Cancer Institute & Harvard Medical School, Boston, MA 02115, USA
- Associate Professor (2007-2013): Samsung Medical Center, Sungkyunkwan Univ. School of Medicine
- Professor (2013-): Samsung Medical Center, Sungkyunkwan Univ. School of Medicine
- Director (2019-): Innovative Institute for Precision Medicine, Samsung Research Institute for Future Medicine, Seoul, Korea

- **Professional Organizations**

- American Association of Cancer Research (AACR),
- American Society of Clinical Oncology (ASCO)
- European Society of Medical Oncology (ESMO)
- Korean Society of Medical Oncology (KSMO)
- Korean Cancer Study Group (KCSG)
- Korean Cancer Association (KCA)
- Korean Association of Internal Medicine

- **Main Scientific Publications:**

1. Park JH, Han K, Hong JY, Park YS, Hur KY, Kang G, Park JO. Changes in Metabolic Syndrome Status are Associated With Altered Risk of Pancreatic Cancer: A Nationwide Cohort Study. *Gastroenterology* 162(2):509-520, 2022 (Corresponding author)
2. Lin W, Noel P, Borazanci EH, Lee J, Amini A, Han IW, Heo JS, Jameson GS, Steinbach M,

15th Annual Meeting of the Korean Society of Medical Oncology & 2022 International Conference

- Woo Y, Fong Y, Cridebring D, Von Hoff DD, Park JO, Han H. Single-cell transcriptome analysis of tumor and stromal compartments of pancreatic ductal adenocarcinoma primary tumors and metastatic lesions. *Genome Med* 12(1):80, 2020 (Corresponding author)
3. Hong JY, Cho HJ, Kim ST, Park YS, Shin SH, Han IW, Lee J, Heo JS, Park JO. Comprehensive molecular profiling to predict clinical outcomes in pancreatic cancer. *Ther Adv Med Oncol* 2021;13:17588359211038478. (Corresponding author)
 4. Kim ST, Kang JH, Lee J, Lee HW, Oh SY, Jang JS, Ah Lee M, Sohn BS, Yoon SY, Choi HJ, Hong JH, Kim MJ, Kim S, Park YS, Park JO, Lim HY. Oxaliplatin Versus Gemcitabine Plus Oxaliplatin as First-Line Therapy for Advanced Biliary Tract Cancers: A Multicenter, Open-Label, Randomized, Phase Three, Non-Inferiority Trial. *Ann Oncol* 30:788-795, 2019 (Corresponding author)